2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Treatment Considerations, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Pharmacology, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, MDS, MPN, CML, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

4582 Evaluating thrombotic risk and hematocrit response from intravenous iron repletion in cytoreduced patients with polycythemia vera

Katherine J. Feder, MD, MS, Jessica Freydman, PharmD2, Arielle Lyon Langer, MD MPH3, Andrew J Webb, PharmD4, Michelle Hyunju Lee, MD5, Chi-Joan How, MD6, Layla N. Van Doren, MD, MBA7, Gabriela Soriano Hobbs, MD8
1 Dana Farber Cancer Institute, Boston, United States, Mass General Brigham Cancer Institute, Boston, United States
2 Massachusetts General Hospital, Boston, United States
3 Brigham and Women's Hospital, Boston, United States
4 Massachusetts General Hospital, Boston, United States
5 Massachusetts General Hospital, Boston, United States
6 Brigham and Women's Hospital, Boston, United States
7 University of California, San Francisco, United States
8 Massachusetts General Hospital, Boston, United States

Background: Erythrocytosis in polycythemia vera (PV) often causes iron deficiency. Although iron deficiency impairs quality of life, iron repletion is generally avoided due to concern for worsening erythrocytosis. Guidelines recommend balancing severity of iron deficiency against erythrocytosis risk. The safety of iron replacement is poorly studied in patients with PV whose hematocrit (HCT) is controlled with cytoreduction. We evaluated HCT control and thrombotic events following intravenous (IV) iron administration in cytoreduced patients with PV.

Methods: Demographics, comorbidities, iron studies, complete blood count, erythropoiesis-stimulating agent (ESA) use, and IV iron administration were extracted using Structured Query Language from the Mass General Brigham electronic health record for patients with PV (per ICD10) receiving cytoreduction from 7/2015-1/2026. Primary outcome was rate of arterial and venous thromboembolic events within 6 months of IV iron administration. Thromboembolic events and atrial fibrillation (afib) were confirmed by manual chart review. Anticoagulation status was determined from pharmacy records and verified against iron infusion times. HCT 4–8 weeks after IV iron was assessed as a secondary endpoint. An IV iron course was defined as IV iron administrations within 30 days of each other or as sequential doses with no gap >14 days. 

Results: Of 710 cytoreduced PV patients, 98 (13.8%) received IV iron. Of these, 48% were male, 90% were White. 29% had heart failure, 36% had chronic kidney disease, and 27% had gastrointestinal bleeding history. 15% had afib, most of whom (87%) were anticoagulated. Prior to iron repletion, median transferrin saturation was 7% (range 2–35), ferritin was 27ng/mL (range 2–1237), and HCT was 33.5% (range 21.6–59.1); 92% of courses were administered when the pre-infusion HCT was <45%. The median number of iron courses was 1 per patient (range 1–15), and 58% of patients received a single course. Median dose per course was 510mg (range 100–1,800), and median cumulative dose per patient was 1000mg (range 100–8785).

Eighty-one patients (83%) had ≥ 6 months of follow-up after IV iron and collectively received 185 courses. Fifty-five courses (29.7%) were administered during anticoagulation for afib or prior thrombosis. Three thrombotic events occurred within 6 months of an iron course (3/185; 1.6%): 1 ST-elevation myocardial infarction, 1 deep vein thrombosis, and 1 pulmonary embolism. One patient had received intermittent anticoagulation; the other 2 were not anticoagulated at the time of thrombosis. Both patients with venous thromboembolism (VTE) had prior VTE, concurrent provoking factors, and HCT <45% at time of event (27.3% and 27.6%); 1 previously tolerated multiple iron courses. The patient with STEMI had a history of prior coronary stenting and a HCT of 49.2% at time of event.

Among 67 patients with available pre- and post-infusion HCT values, 15 (22%) increased from <45% to ≥45% (median post-infusion HCT 47.1%; range 45.0–59.1). This occurred after 18 of 115 evaluable iron courses (15.6%); 1 course was given with an ESA. Among 79 courses with available post-infusion ferritin values, the median was 81ng/mL (range 9–1097). Of 28 patients with post-infusion ferritin <50 ng/mL, 24 (86%) received additional IV iron.

Conclusion: In this cohort of cytoreduced patients with PV, IV iron was associated with rare thrombotic events. The observed thrombotic rate of 1.6% per course within 6 months compares favorably to historic rates of ~1.9-6.8 thrombotic events per 100 person-years in high-risk PV patients on hydroxyurea (Ferrari et al. Haematologica 2019), though direct comparison is limited. Although HCT increased from <45% to ≥45% after 15.6% of evaluable courses, the median post-infusion HCT among these patients was 47.1%, suggesting a modest rise. All thrombotic events occurred in patients with prior thrombosis or substantial cardiovascular risk, and the venous events were accompanied by additional provoking factors. The low median number of iron courses per patient may reflect the absence of clear guidance regarding IV iron use in PV or a sufficient response after initial IV correction as suggested by available post-treatment ferritin values. Our findings suggest IV iron may be safe in selected cytoreduced PV patients with adequate HCT control (HCT<45%) prior to IV iron administration and support prospective studies to define safety and symptomatic benefit.

Katherine J. Feder, MD, MS: Sobi - Consultancy (Includes expert testimony)